Research Study

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of Cemdisiran in Adult Patients With IgA Nephropathy
Principal Investigator 
Sean Barbour

Overview

Body Locations and Systems 
Kidney Disease
ClinicalTrials.gov# 
NCT03841448
Status 
Recruiting
Study Start/End 
Mar 20, 2020 to Dec 31, 2024
Locations 
Diamond Health Care Centre, St. Paul's Hospital
Name/Title 
Zainab Sheriff, Research Coordinator
Phone 
604-682-2344 ext.64744
Purpose of Study 

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.